ELAN Stock Recent News
ELAN LATEST HEADLINES
NEW YORK CITY, NY / ACCESS Newswire / April 29, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN). Investors who purchased Elanco securities prior to November 7, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ELAN.
NEW YORK CITY, NY / ACCESS Newswire / April 24, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN). Investors who purchased Elanco securities prior to November 7, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ELAN.
Sarat Sethi, Managing Partner at DCLA, joins CNBC's "Halftime Report" to detail his latest trades.
NEW YORK CITY, NY / ACCESS Newswire / April 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN). Investors who purchased Elanco securities prior to November 7, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ELAN.
National Parvo Awareness Day raises awareness of canine parvovirus (parvo), the often-fatal puppy disease. Elanco's Canine Parvovirus Monoclonal Antibody (CPMA) is the first-and-only USDA conditionally approved treatment for parvo.
NEW YORK CITY, NY / ACCESS Newswire / April 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN). Investors who purchased Elanco securities prior to November 7, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ELAN.
NEW YORK CITY, NY / ACCESS Newswire / April 17, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN). Investors who purchased Elanco securities prior to November 7, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ELAN.
NEW YORK CITY, NY / ACCESS Newswire / April 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN). Investors who purchased Elanco securities prior to November 7, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ELAN.
NEW YORK CITY, NY / ACCESS Newswire / April 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN). Investors who purchased Elanco securities prior to November 7, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ELAN.
Elanco Animal Health (ELAN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.